Single Cell Profiling of Circulating Tumor Cells: Transcriptional Heterogeneity and Diversity from Breast Cancer Cell Lines
暂无分享,去创建一个
Gyan Bhanot | R. Fabian Pease | Ranjana H. Advani | Robert W. Carlson | James M. Ford | Stephen R. Quake | Melinda L. Telli | Anupama Reddy | Allison W. Kurian | Frank E. Stockdale | AmirAli H. Talasaz | S. Quake | G. Bhanot | Marc Coram | S. Jeffrey | S. Dairkee | R. Pease | R. Advani | Anupama Reddy | Ronald W. Davis | R. Carlson | M. Mindrinos | A. Kurian | Haiyu Zhang | F. Stockdale | A. Talasaz | Glenn Deng | M. Telli | Shruti Sheth | Ashley A. Powell | Haiyu Zhang | Marc A. Coram | Glenn Deng | Joseph A. Mollick | Shruti Sheth | Michael N. Mindrinos | Shanaz H. Dairkee | Stefanie S. Jeffrey | J. Mollick | A. Powell | J. Ford | Shruti N Sheth | Ronald W. Davis
[1] Larry Norton,et al. Tumor Self-Seeding by Circulating Cancer Cells , 2009, Cell.
[2] David Padua,et al. Roles of TGFβ in metastasis , 2009, Cell Research.
[3] D. Mavroudis,et al. Micrometastatic disease in breast cancer: clinical implications. , 2008, European journal of cancer.
[4] T. Fehm,et al. Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status , 2007, Breast Cancer Research.
[5] Ramesh Ramakrishnan,et al. High Throughput Gene Expression Measurement with Real Time PCR in a Microfluidic Dynamic Array , 2008, PloS one.
[6] M. Barcellos-Hoff,et al. Transforming growth factor-β in breast cancer: too much, too late , 2009, Breast Cancer Research.
[7] G. Sauter,et al. Changes in Cytoskeletal Protein Composition Indicative of an Epithelial-Mesenchymal Transition in Human Micrometastatic and Primary Breast Carcinoma Cells , 2005, Clinical Cancer Research.
[8] Stefanie S Jeffrey,et al. A molecular 'signature' of primary breast cancer cultures; patterns resembling tumor tissue , 2004, BMC Genomics.
[9] T. Fehm,et al. HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial , 2010, Breast Cancer Research and Treatment.
[10] D. Mavroudis,et al. Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR , 2011, BMC Cancer.
[11] Kjetil Boye,et al. S100A4 and metastasis: a small actor playing many roles. , 2010, The American journal of pathology.
[12] H. Lenz,et al. EGFR Signaling and Drug Discovery , 2010, Oncology.
[13] J. Engelman,et al. The PI3K pathway as drug target in human cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] L. Kiesel,et al. HER2-Positive Circulating Tumor Cells Indicate Poor Clinical Outcome in Stage I to III Breast Cancer Patients , 2006, Clinical Cancer Research.
[15] W. El-Deiry,et al. Identification and enumeration of circulating tumor cells in the cerebrospinal fluid of breast cancer patients with central nervous system metastases , 2011, Oncotarget.
[16] S. Badve,et al. NF-κB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2 , 2007, Oncogene.
[17] K. Pienta,et al. Global gene expression profiling of circulating tumor cells. , 2005, Cancer research.
[18] John A. Foekens,et al. Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR , 2009, Breast Cancer Research and Treatment.
[19] Mark M Davis,et al. Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device , 2009, Proceedings of the National Academy of Sciences.
[20] Jonathan W. Uhr,et al. Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases , 2004, Clinical Cancer Research.
[21] L. Ylagan,et al. Isolation and Molecular Profiling of Bone Marrow Micrometastases Identifies TWIST1 as a Marker of Early Tumor Relapse in Breast Cancer Patients , 2007, Clinical Cancer Research.
[22] R. Ratan,et al. The Epidermal Growth Factor Receptor Engages Receptor Interacting Protein and Nuclear Factor-κB (NF-κB)-inducing Kinase to Activate NF-κB , 2001, The Journal of Biological Chemistry.
[23] F. Marshall,et al. Progressive epithelial to mesenchymal transitions in ARCaPE prostate cancer cells during xenograft tumor formation and metastasis , 2010, The Prostate.
[24] N. Tonks,et al. Protein tyrosine phosphatases: a diverse family of intracellular and transmembrane enzymes. , 1991, Science.
[25] Jun Liu,et al. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] A. Hackett,et al. MONOCLONAL MARKER THAT PREDICTS EARLY RECURRENCE OF BREAST CANCER , 1987, The Lancet.
[27] C. Punt,et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] J. Thiery. Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.
[29] Caroline Dive,et al. Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Yasuhiro Ito,et al. S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. , 2008, Current cancer drug targets.
[31] E. Gundelfinger,et al. Identification of novel tumor antigens with patient-derived immune-selected antibodies , 2009, Cancer Immunology, Immunotherapy.
[32] Vlad Popovici,et al. Selecting control genes for RT-QPCR using public microarray data , 2009, BMC Bioinformatics.
[33] J. Barrett,et al. PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer , 2010, Clinical Cancer Research.
[34] Raghu Kalluri,et al. The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.
[35] Ronald W. Davis,et al. Distinctive Responsiveness to Stromal Signaling Accompanies Histologic Grade Programming of Cancer Cells , 2011, PloS one.
[36] Larry Norton,et al. Clinical implications of cancer self-seeding , 2011, Nature Reviews Clinical Oncology.
[37] J. Carethers,et al. TGF-beta mediates PTEN suppression and cell motility through calcium-dependent PKC-alpha activation in pancreatic cancer cells. , 2008, American journal of physiology. Gastrointestinal and liver physiology.
[38] Tanja Fehm,et al. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients , 2009, Breast Cancer Research.
[39] Alison Stopeck,et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.
[40] I. Fabregat,et al. Role of CXCR4/SDF-1 alpha in the migratory phenotype of hepatoma cells that have undergone epithelial-mesenchymal transition in response to the transforming growth factor-beta. , 2009, Cellular signalling.
[41] Jaap M J den Toonder,et al. Circulating tumor cell isolation and diagnostics: toward routine clinical use. , 2011, Cancer research.
[42] S. Jeffrey,et al. Basal carcinoma of the breast revisited: an old entity with new interpretations , 2008, Journal of Clinical Pathology.
[43] S. Jeffrey,et al. Genomics-based prognosis and therapeutic prediction in breast cancer. , 2005, Journal of the National Comprehensive Cancer Network : JNCCN.
[44] J. Carethers,et al. RAS/ERK modulates TGFbeta-regulated PTEN expression in human pancreatic adenocarcinoma cells. , 2007, Carcinogenesis.
[45] Julian Parkhill,et al. Single-cell genomics , 2008, Nature Reviews Microbiology.
[46] A. Lluch,et al. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. , 2010, Cancer treatment reviews.
[47] S. Digumarthy,et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology , 2007, Nature.
[48] R. F. Harvey,et al. A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITY , 1980, The Lancet.
[49] Ruud H. Brakenhoff,et al. Detection, clinical relevance and specific biological properties of disseminating tumour cells , 2008, Nature Reviews Cancer.
[50] R. Weinberg,et al. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.
[51] Sanjay Shete,et al. uPAR and HER-2 gene status in individual breast cancer cells from blood and tissues , 2006, Proceedings of the National Academy of Sciences.
[52] S. Bodovitz,et al. Single cell analysis: the new frontier in 'omics'. , 2010, Trends in biotechnology.
[53] Stephen R Quake,et al. Solving the "world-to-chip" interface problem with a microfluidic matrix. , 2003, Analytical chemistry.
[54] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[55] S. Jeffrey,et al. Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype , 2010, British Journal of Cancer.
[56] S. Jeffrey,et al. Oxidative stress pathways highlighted in tumor cell immortalization: association with breast cancer outcome , 2007, Oncogene.
[57] N. Tonks,et al. The leukocyte common antigen (CD45): a putative receptor-linked protein tyrosine phosphatase. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[58] Annibale Biggeri,et al. Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients , 2009, Breast Cancer Research and Treatment.
[59] W. J. Allard,et al. Circulating tumor cells predict survival in patients with metastatic prostate cancer. , 2005, Urology.
[60] W. Gerald,et al. Identifying site-specific metastasis genes and functions. , 2005, Cold Spring Harbor symposia on quantitative biology.
[61] R. Ratan,et al. The epidermal growth factor receptor engages receptor interacting protein and nuclear factor-kappa B (NF-kappa B)-inducing kinase to activate NF-kappa B. Identification of a novel receptor-tyrosine kinase signalosome. , 2001, The Journal of biological chemistry.
[62] C. Loehberg,et al. Comparison of estrogen and progesterone receptor status of circulating tumor cells and the primary tumor in metastatic breast cancer patients. , 2011, Gynecologic oncology.
[63] G. Hortobagyi,et al. Circulating tumor cells in immunohistochemical subtypes of metastatic breast cancer: lack of prediction in HER2-positive disease treated with targeted therapy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[64] H. Feiler,et al. Immutable functional attributes of histologic grade revealed by context-independent gene expression in primary breast cancer cells. , 2009, Cancer research.